Comprehensive molecular profiling of 5,175 esophagogastric cancer (EGC) patients identified distinct molecular signatures for early-onset (< 50 years of age, EOEGC, n=530) versus average-onset (AOEGC, n=4,645) tumors.
EOEGC has increased frequency of CDH1 mutations, ARHGAP26 fusions, enrichment of epithelial mesenchymal transition (EMT) and angiogenesis pathways, decreased MAPK pathway activity, decreased frequency of TMB-high and dMMR/MSI-H, and a unique immune cell infiltrate with decreased M1 macrophages and increased M2 macrophages.
These unique differential characteristics present therapeutic opportunities but also demonstrate the limitations of currently approved therapies in this subset of patients.
Abstract Purpose CRTC1::TRIM11 cutaneous melanocytic tumors are a recently described uncommon entity almost exclusively reported as arising in the skin with fewer than 70 described… […]
Differential Impact of Tumor-Derived ESR1 Mutations on Elacestrant Benefit in Metastatic Breast Cancer
Abstract Purpose: ESR1 mutations are a well-established mechanism of endocrine therapy resistance in estrogen receptor (ER)–positive metastatic breast cancer and are a biomarker for treatment… […]
